Basic Information | Post buying leads | Suppliers | Cas Database |
Name |
25I-NBOH HCL |
EINECS | N/A |
CAS No. | 919797-20-9 | Density | 1.493±0.06 g/cm3(Predicted) |
PSA | 50.72000 | LogP | 3.73720 |
Solubility | N/A | Melting Point |
N/A |
Formula | C17H20INO3 | Boiling Point | 497.0±45.0 °C(Predicted) |
Molecular Weight | 413.255 | Flash Point | N/A |
Transport Information | N/A | Appearance | N/A |
Safety | Risk Codes | N/A | |
Molecular Structure | Hazard Symbols | N/A | |
Synonyms |
NBOH-2CI;25I-NBOH;25I-NBOH HCL;Cimbi-27; |
Article Data | 4 |
25I-NBOH (NBOH-2CI, Cimbi-27, 2-C-I-NBOH) is a derivative of the phenethylamine derived hallucinogen 2C-I that was discovered in 2006 by a team at Purdue University. It acts as a potent agonist for the 5HT2A receptor, with a Ki of 0.061nM at the human 5HT2A receptor, similar to the better-known compound 25I-NBOMe, making it some twelve times the potency of 2C-I itself. In vitro tests showed this compound acted as an agonist but animal studies have not been reported. While the N-benzyl derivatives of 2C-I were significantly increased in binding activity to 5HT2A receptor fragments, compared to 2C-I, the N-benzyl derivatives of DOI were less active, compared to DOI.
25I-NBOH is notable as one of the most selective agonist ligands for the 5-HT2A receptor with an EC50 value of 0.074 nM and more than 400x selectivity over the 5-HT2C receptor.